Feb XXVIII: Several new drugs and promising therapies, such as chimeric antigen receptor T-cell therapy, have ushered in a “renaissance” for lupus, according to a speaker at the symposium Basic and Clinical Immunology for the Busy Clinician.
Secundum Emily Littlejohn, DO, MPH, Clinici Cleveland, elementorum monocloalium et interferonum sunt duae curationes potentiales additae pro erythematoso systemico lupus ab anno 2020 ortae.
“2020 is what many of us consider the lupus renaissance,” Littlejohn told attendees during the hybrid meeting. “This is a time where, finally, we had many drugs entering the armamentarium very quickly.”
Ut legere licet: CAR in Sina Lorem T Cell
According to Littlejohn, there have been a lot of exciting new treatments for SLE since the quick approvals of belimumab (Benlysta, GSK), voclosporin (Lupkynis, Aurinia), and anifrolumab (Saphnelo, AstraZeneca). CAR T-cell therapy might be the most exciting of these.
“This is used in the oncology world—we have seen it in [B-cell acute lymphoblastic leukemia], [B-cell non-Hodgkin’s lymphoma] and mantel cell lymphoma,” Littlejohn said. “The question is: What about in our diseases?”
Littlejohn affirmavit omnes aegros, qui in studiis Germanicis participes sunt, qui quinque aegros cum multi-organo implicatione profitebantur, statum consequi posse, in quo nephritis cessavit. Littlejohn addidit eventus spem praebere, sed periculum liberorum non est justo.
Ut legere licet: CAR T Cell Lorem multa myeloma in Sinis
"Ingens periculum est syndrome cytokini emissio - ICANS in specie - quod est valde FORMIDULOSUS" dixit.
Multum in hoc spatio promissionis esse arbitror, considerans hos quinque aegros [tractatus cum CAR-T cellis therapiis] et quam bene fecerunt,” addidit.
Alternatives ad CAR T-cell Lorem are in development. These include litifilimab (BIIB059, Biogen), interferon—kinoid, obinutuzumab (Gazyva, Genentech) and iberdomide (Bristol Myers Squibb).
Interfe-kinoid fines in maximis iudiciis non occurrit, et futurum "incertum" dixit Littlejohn.
Ut legere licet: CAR T Cell Lorem pretium in Sinis
"Litifiliab initio studuit aegros cutaneo lupus, summa 132," inquit Littlejohn. "Quae inuenerunt quod primas terminos cum diminutione in cute CLASI viginti octo 16 convenerunt."
Accedit, quod medicamentum valuit in reducendo numerum articulorum in morbo activo, secundum dictum Littlejohnium.
Denique obinutuzumab eius primarium finem cum lupus nephritis patientibus occurrit, Littlejohn dixit.
